Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's

Eligibility

Inclusion Criteria: * Diagnosis of Parkinson's disease (PD) * Approved (or planning on) for subthalamic nucleus (STN) deep brain stimulation (DBS) * Willingness to withdraw from clinical medication regimen when necessary for research visits * Ability to provide informed consent Exclusion Criteria:

Locations